Abby E. Rudolph

Durability of RSV Prefusion F Vaccine Protection across Two RSV Seasons

BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of hospitalization and death among older adults. Although first-season vaccine effectiveness against RSV-related hospitalization has been demonstrated for the bivalent RSV prefusion F protein-based vaccine (RSVpr...

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults

BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-ass...

Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025–2026 formula in the pediatric population aged 5–17 years at high risk of severe outcomes from COVID-19 in the United States

INTRODUCTION: This study evaluated the potential public health impact of receiving Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula, in the US pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19. RESEARCH DESIGN AND METHODS: A previously...